Biliary Tract Neoplasms: all 492 studies
Page 4 of 5. Open to participants first (191), then studies with results posted, then the rest; newest registration first within each.
- Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex)CompletedNCT05044065Not applicable
- The Registry of Genetic Alterations of Taiwan Biliary Tract CancerActive, not recruitingNCT05036486
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerTerminatedNCT05009953Phase 2
- Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract CancerStatus unknownNCT04984980Phase 2
- GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract CancerStatus unknownNCT04979663Phase 1/2
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
- Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)Status unknownNCT04907864Phase 2
- New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)CompletedNCT04896931
- Biomarker Discovery in Patients With Advanced Biliary Tract CancerCompletedNCT04871321
- A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical ResectionStatus unknownNCT04856761
- A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerCompletedNCT04838964Phase 2
- A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerStatus unknownNCT04837508Phase 2
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerStatus unknownNCT04809142Phase 3
- Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary StenosisCompletedNCT04801719Not applicable
- Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract CancerWithdrawnNCT04796454Phase 2
- A Study of HA121-28 Tablets in Advanced Biliary Tract CancerTerminatedNCT04784520Phase 2
- Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
- Predicting Disease Progression and/or Recurrence in CancerCompletedNCT04776837
- A Phase 1/2 Study of SC-43 in Combination With CisplatinStatus unknownNCT04733521Phase 1/2
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT04727996Phase 2
- Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract CancerTerminatedNCT04727541Phase 2
- Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line TherapyCompletedNCT04722133Phase 2
- Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
- A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract CancerStatus unknownNCT04692051Phase 2
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
- Lenvatinib in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04656249Phase 2
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
- Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
- Observational Study on Patients With Hepatobiliary TumorsStatus unknownNCT04637048
- A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract CancerStatus unknownNCT04608786Phase 1
- LAMS Choledochoduodenostomies: With or Without Coaxial Plastic StentCompletedNCT04595058Not applicable
- CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary CancersStatus unknownNCT04584996
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsActive, not recruitingNCT04584008Not applicable
- An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract CancerNo longer availableNCT04578444
- A Trial of SHR1258 in Patients With Biliary Tract CancerWithdrawnNCT04571710Phase 2
- Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid BiopsiesCompletedNCT04566614
- Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract CancerTerminatedNCT04561453
- A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor PatientsTerminatedNCT04492033Phase 1/2
- Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled EpiduralStatus unknownNCT04352023Phase 2
- Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder CancerStatus unknownNCT04333927Phase 2
- A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract CancerActive, not recruitingNCT04329429Phase 2
- Neoadjuvant Gemcitabine Plus Cisplatin with or Without Durvalumab in Resectable Biliary Tract CancerActive, not recruitingNCT04308174Phase 2
- Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract CancerStatus unknownNCT04300959Phase 2
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsTerminatedNCT04278144Phase 1/2
- HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTCCompletedNCT04217954Phase 2
- Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
- A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract CancerWithdrawnNCT04186156Phase 2
- Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04111380Phase 2
- Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)CompletedNCT04068168
- Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract CancerStatus unknownNCT04027764Phase 2
- Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerActive, not recruitingNCT04005339Phase 2
- A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTCStatus unknownNCT04004234Phase 1/2
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract CancerStatus unknownNCT03943043Phase 1/2
- Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract CancerCompletedNCT03937895Phase 1/2
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerCompletedNCT03929666Phase 2
- COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract CancerStatus unknownNCT03898895Phase 2
- A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsStatus unknownNCT03873532Phase 2/3
- The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract AdenocarcinomaCompletedNCT03830606Phase 2
- Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnNCT03818997Phase 2
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract CancersActive, not recruitingNCT03801083Phase 2
- A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract CancerCompletedNCT03796429Phase 2
- Adjuvant Chemotherapy for Biliary Tract Cancer After Curative ResectionStatus unknownNCT03779035Phase 3
- FOLFIRINOX for 2nd-line Treatment of BTCCompletedNCT03778593Phase 2
- Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract CancerWithdrawnNCT03768531Phase 2
- Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome SequencingStatus unknownNCT03718897
- A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint InhibitorsActive, not recruitingNCT03695952
- Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTCCompletedNCT03673072Phase 3
- Xenotransplantation of Primary Cancer Samples in Zebrafish EmbryosStatus unknownNCT03668418
- Monitoring of patIents With Microdialysis Following PancreaticoduodenectomyActive, not recruitingNCT03631173Not applicable
- Trastuzumab in HER2-positive Biliary Tract CancerCompletedNCT03613168Phase 2
- Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract CancerCompletedNCT03524508Phase 2
- The Diagnostic Value of Combinatory EUS and ERCP in Unclear LesionsCompletedNCT03504293
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedNCT03486678Phase 2
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingNCT03482102Phase 2
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCCompletedNCT03478488Phase 3
- mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First LineCompletedNCT03464968Phase 2
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract CancerActive, not recruitingNCT03440450Phase 1
- Apatinib for Advanced Biliary CarcinomaStatus unknownNCT03427242Phase 2
- Molecular Profiling of Advanced Biliary Tract CancersWithdrawnNCT03419247Not applicable
- Patient Activation Through Counseling, Exercise and MobilizationCompletedNCT03411200Not applicable
- Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract CancerCompletedNCT03406299Phase 2
- Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract CancerCompletedNCT03358849Phase 1
- Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCsStatus unknownNCT03311789Phase 1/2
- Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract CancersTerminatedNCT03291899Phase 2
- Pembrolizumab in Biliary Tract CancerCompletedNCT03260712Phase 2
- Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerCompletedNCT03231176Phase 2
- Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemStatus unknownNCT03185988Phase 2
- Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary CancersCompletedNCT03162510Phase 1
- Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract CancersStatus unknownNCT03144856Phase 2
- Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract CancerWithdrawnNCT03129074Phase 2
- FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyWithdrawnNCT03110510Phase 2
- Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyStatus unknownNCT03110484Phase 2
- Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03110328Phase 2
- A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid TumoursCompletedNCT03082053Phase 1
- Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic CholangiocarcinomaCompletedNCT03079427Phase 2
- EUS BD vs ERCP TP for Pancreatic CancerStatus unknownNCT03063554Not applicable
- Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerActive, not recruitingNCT03046862Phase 2